The active, programmed termination of inflammatory responses through coordinated molecular and cellular mechanisms that restore tissue Homeostasis. Unlike passive decay, resolution is an energy-requiring process driven by Specialized pro-resolving mediators (SPMs), temporal lipid mediator class switching, and orchestrated immune cell phenotype transitions that clear debris and initiate tissue repair.
Think of inflammation resolution like a construction site cleanup after an emergency repair job. When a water pipe bursts (tissue injury), the first responders arrive with hammers and saws (neutrophils releasing pro-inflammatory signals), tearing up floors and walls to access the damage. This creates chaos—debris everywhere, water flowing, alarms ringing. But here's the critical part: the cleanup isn't just "everyone goes home and the mess slowly disappears." Instead, a specialized cleanup crew arrives (macrophages switched to M2 phenotype), guided by new instructions (SPMs) that tell them exactly what to bag, what to recycle, and what to rebuild. They actively vacuum up the dead workers who completed their job (efferocytosis of apoptotic neutrophils), sort the debris, and signal the restoration team to lay new flooring (tissue regeneration). If this cleanup crew never arrives—or arrives but can't do their job because they lack the right tools (insufficient omega-3s for SPM synthesis)—you get a chronic construction site: debris piling up, alarms still ringing, inflammation that never ends. The switch from demolition to restoration is the lipid mediator class switch: PGE2 and LTB4 (demolition orders) get replaced by resolvins and maresins (cleanup and rebuild orders).
Resolution of inflammation proceeds through a precisely timed molecular cascade involving lipid mediator class switching and immune cell reprogramming:
Phase 1: Lipid Mediator Class Switch
Phase 2: SPM Receptor Signaling
Phase 3: Cellular Reprogramming
- Neutrophil fate:
- Resolvins + Maresins → ↓neutrophil chemotaxis (block CCL2, CXCL1)
- ↑neutrophil apoptosis via caspase-3 activation
- ↓NETosis (prevents chromatin trap formation)
- Macrophage phenotype switch:
- M1 (pro-inflammatory) → M2 (pro-resolution) via STAT6, PPARγ activation
- M2 macrophages upregulate:
- CD206 (mannose receptor) for debris recognition
- TGF-beta, IL-10 (anti-inflammatory cytokines)
- Arginase-1 (L-arginine → ornithine + urea, supports collagen synthesis)
- Enhanced Efferocytosis:
- Apoptotic neutrophils expose phosphatidylserine → recognized by TIM-4, MerTK on macrophages
- Engulfment triggers TGF-beta release → reinforces M2 phenotype
- "Silent" phagocytosis: no IL-1β or TNF-α release during debris clearance
Phase 4: Tissue Regeneration
- SPMs activate:
- VEGF (vascular endothelial growth factor) → angiogenesis
- Stem cell mobilization via CXCR4 regulation
- Collagen deposition via TGF-beta signaling
- Neuronal protection:
- NPD1 (neuroprotectin D1) ↓COX-2 in neurons, ↑Bcl-2 (anti-apoptotic)
- Preserves IENF density (intraepidermal nerve fiber density)
- ↓ATF3 expression (activating transcription factor 3, neuronal stress marker)
graph TD
A[Tissue Injury] --> B[PLA2G7 activation]
B --> C[AA release]
B --> D[EPA/DHA release]
C --> E[COX-2/5-LOX]
E --> F["PGE2 + LTB4"]
F --> G[Neutrophil recruitment]
G --> H[Peak inflammation 4-6h]
H --> I[COX-2 acetylation/S-nitrosylation]
I --> J[Lipoxin production from AA]
D --> K[15-LOX/12-LOX/5-LOX]
K --> L[Resolvins, Protectins, Maresins]
J --> M[ALX-FPR2 activation]
L --> M
M --> N["↓NF-κB, ↑SOCS3"]
N --> O[Neutrophil apoptosis]
N --> P["M1→M2 macrophage switch"]
P --> Q[Efferocytosis]
Q --> R["TGF-β + IL-10 release"]
R --> S[Tissue regeneration]
S --> T[Homeostasis restored]
Failed resolution of inflammation is the mechanistic core of most chronic inflammation-driven diseases: atherosclerosis, rheumatoid arthritis, Alzheimer's Disease, Type 2 Diabetes, inflammatory bowel disease, and chronic pain syndromes. In the 5 plus 2 metamodel, defective resolution represents a breakdown in metabolic flexibility (inadequate substrate for SPM synthesis), allostatic load (chronic unresolved stress responses), and the selfish immune system (immune cells unable to complete their program and return to surveillance mode).
Clinical Thresholds & Biomarkers:
- Omega-3 index <8% predicts impaired resolution capacity
- SPMs measurable in plasma: RvD1 <50 pg/mL, RvE1 <30 pg/mL suggest deficiency
- Resolution interval: healthy = 24-48 hours for acute inflammation; >72 hours indicates resolution failure
- IENF density (intraepidermal nerve fiber): normal >10 fibers/mm; <5 fibers/mm = small fiber neuropathy from unresolved inflammation
- ATF3 (neuronal stress marker): elevated in DRG neurons with chronic inflammation exposure
Intervention Strategy:
- Support substrate availability: EPA 2-3 g/day + DHA 1-2 g/day to ensure adequate SPM precursors
- Avoid resolution blockers: Chronic NSAIDs inhibit COX-2, blocking both PGE2 (needed early) AND lipoxin synthesis (needed for resolution). Use NSAIDs only in acute phase (<72 hours), then discontinue.
- Timing matters: Aspirin in low doses (75-100 mg) acetylates COX-2 → produces aspirin-triggered resolvins (AT-RvD1), but high-dose chronic use blocks all COX-2 products
- Support efferocytosis: Adequate vitamin D (>30 ng/mL) and vitamin A enhance macrophage phagocytic capacity
- Address root causes: Resolution failure often reflects metabolic dysfunction, gut dysbiosis (SCFA deficiency impairs M2 polarization), or chronic psychological stress (cortisol blocks M1→M2 switch)
Evolutionary Mismatch Context:
Modern omega-6 to omega-3 ratio averages 15:1 (evolutionary baseline ~1:1), creating a pro-inflammatory eicosanoid bias. Combine this with chronic stress (perpetual cortisol → glucocorticoid resistance), sedentary behavior (reduced muscle-derived SPM potentiators), and processed food (trans fats compete for LOX enzymes), and you have a population structurally incapable of resolving inflammation.
- Resolution is an active process requiring ATP, not passive inflammatory decay
- Lipid mediator class switching is temporally controlled: PGE2 peaks at 4-6h, lipoxins at 8-12h, resolvins at 12-24h post-injury
- DHA is the precursor for D-series resolvins, protectins, and maresins; EPA produces E-series resolvins
- Aspirin in low doses (75-100 mg) acetylates COX-2 → produces aspirin-triggered resolvins (AT-RvD1, AT-RvD3) with 10x potency
- Efferocytosis is "silent"—no pro-inflammatory cytokine release during apoptotic cell clearance
- M2 macrophages produce arginase-1, which metabolizes L-arginine to ornithine (collagen precursor) rather than nitric oxide (M1 function)
- Resolution interval in healthy individuals: 24-48 hours; >72 hours = resolution failure
- SPMs are rapidly metabolized by eicosanoid oxidoreductase and CYP450 enzymes (half-life ~30 minutes), requiring continuous synthesis
- IENF density correlates with resolution capacity—chronic inflammation destroys small nerve fibers, measurable by skin biopsy
- ATF3 (activating transcription factor 3) is induced in dorsal root ganglion neurons by unresolved inflammation → neuropathic pain substrate
- Omega-3 index <4% = severe deficiency; 4-8% = intermediate; >8% = optimal for resolution
- Peripheral neuropathy from diabetes or chemotherapy involves failed resolution—damaged nerves cannot clear inflammatory debris
- Specialized pro-resolving mediators (SPMs) — the molecular mediators that actively drive resolution
- Lipid mediator class switching — temporal shift from pro-inflammatory to pro-resolving lipid signals
- Efferocytosis — macrophage clearance of apoptotic neutrophils, essential for completing resolution
- M2 macrophages — resolution-phase macrophage phenotype producing IL-10, TGF-β, and arginase-1
- arachidonic acid — omega-6 fatty acid producing both early inflammatory signals (PGE2, LTB4) and later lipoxins
- DHA — omega-3 fatty acid precursor for D-series resolvins, protectins (NPD1), and maresins
- EPA — omega-3 fatty acid precursor for E-series resolvins
- prostaglandin E2 — early pro-inflammatory signal that peaks before resolution begins
- Leukotriene B4 — neutrophil chemoattractant that must be replaced by resolvins for resolution
- Lipoxins — first-generation SPMs derived from arachidonic acid via acetylated/S-nitrosylated COX-2
- Resolvins — potent SPMs (RvD1-6, RvE1-3) that halt neutrophil recruitment and promote M2 switch
- Protectins — neuroprotective SPMs (NPD1) that preserve nerve fiber density
- Maresins — macrophage-derived SPMs that enhance efferocytosis and tissue regeneration
- COX-2 — enzyme producing both PGE2 (early) and lipoxins (late) depending on post-translational modification
- PLA2G7 — phospholipase A2 that liberates fatty acid substrates for eicosanoid/SPM synthesis
- NSAIDs — block COX-2, impairing both inflammation AND resolution; use only acutely
- aspirin — low-dose acetylates COX-2 to produce aspirin-triggered resolvins
- omega-3 fatty acids — essential dietary substrates for SPM synthesis; modern deficiency = resolution failure
- chronic inflammation — the state resulting from failed or incomplete resolution
- inflammation — the acute process that resolution terminates
- ALX-FPR2 receptor — key receptor for resolvins and lipoxins on neutrophils and macrophages
- NF-kB — transcription factor suppressed by SPM signaling, reducing pro-inflammatory gene expression
- SOCS3 — suppressor of cytokine signaling upregulated by resolvins to dampen inflammatory responses
- TGF-beta — anti-inflammatory cytokine released during efferocytosis, reinforcing M2 phenotype
- IL-10 — immunosuppressive cytokine produced by M2 macrophages during resolution
- IENF density — intraepidermal nerve fiber density, damaged by unresolved inflammation
- ATF3 — neuronal stress marker elevated in chronic inflammation, linked to neuropathic pain
- peripheral neuropathy — often results from failed resolution in diabetes, chemotherapy, or autoimmune disease
- neuropathic pain — sustained by unresolved neuroinflammation and loss of nerve fiber integrity
- wound healing — depends on successful resolution to transition from inflammation to regeneration
- atherosclerosis — driven by defective resolution in arterial plaques (impaired efferocytosis)
- metabolic flexibility — required to generate ATP and substrates for active resolution processes
- gut dysbiosis — impairs SCFA production, which supports M2 macrophage polarization
- psychological stress — chronic cortisol exposure → glucocorticoid resistance → failed M1→M2 switch
- Homeostasis — the physiological state restored by successful resolution